At GloballuxRx, we create cutting-edge, patient-centered drug formulations that improve efficacy, safety, and quality of life — while boosting patient adherence and significantly reducing total treatment costs.
About us
GloballuxRx is a science-driven pharmaceutical company headquartered in Latvia with R&D labs in India. Our seasoned team combines EU quality oversight with cost-efficient global innovation to solve tough formulation challenges for patients worldwide.
Vision
Empowering patients, payers, and healthcare providers with innovative, value-added medicines that improve treatment outcomes and quality of life.
Mission
Driven by innovation and excellence, we create advanced drug formulations for global markets, overcoming medical hurdles and delivering lasting health benefits.
Our Strategic focus
Rapid, cost-effective development through know-how R&D design and lean operations. Differentiated commercial partnerships that speed market access and maximize stakeholder value. Inspired, empowered colleagues united by a feedback-rich culture.
Care Without Boundaries From hospitals to homes, critical care to daily maintenance—our delivery platforms are built to meet patients wherever they are. We enable seamless transitions across settings, supporting more flexible, responsive care.
Empowering Simplicity in Complexity Whether in the hands of a caregiver, a first responder, or the patient themselves, our solutions simplify treatment. Intuitive, low-burden formats reduce the need for frequent dosing and make complex regimens more manageable.
Precision for Real-World Needs Therapies shouldn’t depend on ideal conditions. Our technologies are engineered for consistent performance—ensuring medicines work predictably, when and where they’re needed most.
Ready for the Urgent and the Everyday From emergency response to long-term care, we design for both speed and sustainability—delivering therapeutic impact without compromise.
Pipeline
GlobalLuxRx is advancing 20-plus value-added generics and 505(b)(2) assets across oncology, infectious diseases, and chronic care.
Key 2025–2027 launch candidates include food-effect–neutral oncology tablets, swallow-friendly tabs for and nanotechnology enhanced formulations.
Contact maxim.vlasenko@globalluxrx.com about our pipeline
Globallux
Advancing the Future of Specialty Pharmaceuticals
At Globallux, we are committed to transforming complex drug development into scalable, high-impact solutions that drive better health outcomes and create long-term value across the pharmaceutical value chain.
With deep expertise in regulatory strategy, complex generics, and differentiated drug delivery platforms, our portfolio is designed to meet the evolving needs of patients, caregivers, and global healthcare systems.
Enhancing Patient Compliance & Therapeutic Adherence Our formulations are engineered to optimize convenience, reduce dosing complexity, and improve real-world treatment effectiveness — a critical driver of outcomes and long-term brand sustainability.
Complex Generics & 505(b)(2) Product Development We leverage the 505(b)(2) regulatory pathway and advanced formulation technologies to bring differentiated products to market faster, with reduced risk and enhanced exclusivity potential.
First-to-File and NCE-1 Market StrategiesGloballux actively targets high-value opportunities through early entry and lifecycle extension, focusing on NCE-1 and first-wave generic launches that offer significant commercial upside.
Geriatric & Pediatric-Friendly Formulations Our age-adapted drug delivery systems are designed with real-world use in mind — ensuring accessibility, tolerability, and ease of administration for the most vulnerable patient groups.
Value-Driven Oral Solid Dosage Technologies By combining innovation with unmet clinical needs, our oral solid products achieve superior patient outcomes and support brand differentiation in crowded markets.
Caregiver-Oriented Solutions We recognize the growing role of caregivers in treatment adherence. Our product designs simplify administration, reduce burden, and support treatment success in home and outpatient settings.
.png)
.png)
.png)